Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.60 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 5/20 | 0.60 |
| ▸ | CA1 | P00915 | 5/20 | 0.60 |
| ▸ | CA2 | P00918 | 5/20 | 0.60 |
| ▸ | CA9 | Q16790 | 5/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886736 | 0.94 | FFAR1 (0.56) | S1PR1S1PR3S1PR5CA12CA1 | |
| SCHEMBL13886735 | 0.90 | NPC1 (0.57) | S1PR1S1PR3CA12CA1CA2 | |
| SCHEMBL15092809 | 0.88 | CA12 (0.52) | S1PR1S1PR3S1PR5CA12CA1 | |
| SCHEMBL7275476 | 0.88 | BCHE (0.56) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL15092810 | 0.88 | MAPT (0.64) | CA12CA1CA2CA9SIGMAR1 | |
| SCHEMBL1541945 | 0.87 | CA1 (0.64) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL5468072 | 0.87 | NPSR1 (0.61) | SIGMAR1POLBNPSR1IDO1 | |
| SCHEMBL22102023 | 0.87 | NPSR1 (0.61) | SIGMAR1POLBNPSR1IDO1 | |
| SCHEMBL4583683 | 0.87 | POLB (0.65) | SIGMAR1POLBNPSR1IDO1 | |
| SCHEMBL30521147 | 0.87 | CA1 (0.60) | S1PR1S1PR3S1PR5CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391199-B1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20070088027-A1 | Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-04-19 | — | — | US | disclosed |
| US-20070088027-A1 | Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-04-19 | — | — | US | disclosed |
| US-20070088027-A1 | Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-04-19 | — | — | US | disclosed |
| US-7179817-B2 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7179817-B2 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7179817-B2 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040224941-A1 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-11 | — | — | US | disclosed |
| EP-1391199-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088027-A1 | Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient | EDF1, FFAR1, EDNRA | S1PR1 405/4885S1PR3 1027/4885S1PR5 854/4885 |
| US-20040224941-A1 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | EDF1, FFAR1, VCAM1 | S1PR1 374/4885S1PR3 1073/4885S1PR5 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.